Rocky Ganske appointed as illumiSonics Inc., President, and CEO
Waterloo, Canada, June 1, 2020 -(illumisonics.com)- illumiSonics Inc., a developer of PARS™ Technology, is pleased to announce that Rocky Ganske, the former CEO of CellAegis Devices Inc., will be joining as illumiSonics President and CEO effective June 1, 2020.
Mr. Ganske brings over 3 decades of both public and private company experience in the medical devices, diagnostics, and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures.
Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies. He led CellAegis Devices Inc. as the CEO for the last 10 years transitioned the technology out of Sick Kids Hospital, Toronto into a commercial product with CE Mark and Health Canada approval used in several multinational controlled trials, in cardiovascular, stroke, and kidney reperfusion damage.
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on real-time proteomic analysis utilizing proprietary diffractive optics technology. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s commercial platform in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.
Mr. Ganske held the position of Chief Operating Officer at Third Wave Technologies (TWTI) in Madison, WI. During his eight-year tenure at TWTI, Mr. Ganske was imperative in setting the operational vision and tactical implementation that grew TWTI from a company with great technology to a fully operational company with over $40M of revenue. Third Wave debuted on Nasdaq in February 2001 in an $83 Million IPO and was bought by Hologic for over $300M. Prior to Third Wave, Mr. Ganske held various operational, engineering and regulatory management positions over 18 years, with Becton Dickinson and Company (BDX).
About illumiSonics Inc.
illumiSonics Inc., develops, patents and commercialized PARS™ advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Our proprietary PARS™ photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS™ measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. PARS™ is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS™ to maintain all of the advantages of photoacoustic imaging while addressing its short comings which provides incredible flexibility in how it can be deployed. illumiSonics is a privately owned Canadian company. For more information visit http://www.illumisonics.com/ or email us at [email protected].
Mr. Ganske brings over 3 decades of both public and private company experience in the medical devices, diagnostics, and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures.
Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies. He led CellAegis Devices Inc. as the CEO for the last 10 years transitioned the technology out of Sick Kids Hospital, Toronto into a commercial product with CE Mark and Health Canada approval used in several multinational controlled trials, in cardiovascular, stroke, and kidney reperfusion damage.
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on real-time proteomic analysis utilizing proprietary diffractive optics technology. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s commercial platform in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.
Mr. Ganske held the position of Chief Operating Officer at Third Wave Technologies (TWTI) in Madison, WI. During his eight-year tenure at TWTI, Mr. Ganske was imperative in setting the operational vision and tactical implementation that grew TWTI from a company with great technology to a fully operational company with over $40M of revenue. Third Wave debuted on Nasdaq in February 2001 in an $83 Million IPO and was bought by Hologic for over $300M. Prior to Third Wave, Mr. Ganske held various operational, engineering and regulatory management positions over 18 years, with Becton Dickinson and Company (BDX).
About illumiSonics Inc.
illumiSonics Inc., develops, patents and commercialized PARS™ advanced optical imaging systems for a wide range of pre-clinical and clinical applications. Our proprietary PARS™ photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS™ measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. PARS™ is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS™ to maintain all of the advantages of photoacoustic imaging while addressing its short comings which provides incredible flexibility in how it can be deployed. illumiSonics is a privately owned Canadian company. For more information visit http://www.illumisonics.com/ or email us at [email protected].
Download Here
| Rocky Ganske Press Release |